Safety and Efficacy of tPBM for Epileptiform Activity in Autism

Inclusion Criteria: * Autism Spectrum Disorder (diagnosed as Autistic Disorder on the ADOS-2 or the ADI-R). * Between 4 and 12 years of age, at baseline. * Autism severity of moderate or higher (≥4) under the 7-item clinical global impression-severity scale. Moderate level of autism severity (4) is defined by the diagnosis of ASD with language impairment. * Ability to maintain all ongoing complementary, dietary, traditional, and behavioral treatments constant for the study period. * Unchanged complementary, dietary, traditional, and behavioral treatments for two months prior to study entry * Ability to tolerate procedures, as determined at the discretion of the investigator. * At least one 24hr EEG with data in EDF format that is accessible to investigators. Exclusion Criteria: * Significant self-abusive or violent behavior or evidence of suicidal ideation, plan or behavior * Severely affected children as defined by CGI-Severity Standard Score = 7 (Extremely Ill) * Severe prematurity (\<34 weeks gestation) as determined by medical history * Current uncontrolled gastroesophageal reflux disease since GERD can cause movements that appear like seizures * Genetic syndromes * Congenital brain malformations * Any medical condition that the PI determines could jeopardize the safety of the study subject or compromise the integrity of the data. * Failure to thrive or Body Mass Index \&lt; 5%ile or \&lt;5%ile for weight (male \&lt;11.2kg; female \&lt;10.8kg by CDC 2000 growth charts) at the time of the study. * Concurrent treatment with drug that would significantly interact with treatment. * • Stimulants * • Anti-Psychotics * • Antihistamines * Excessive Hair that the caregivers are unwilling or unable to shave or braid. * Inability to tolerate the required dosage of tPBM treatment due to sensory issues.